Milestone Pharmaceuticals (MIST) Depreciation & Amortization (CF) (2018 - 2026)

Milestone Pharmaceuticals (MIST) has 9 years of Depreciation & Amortization (CF) data on file, last reported at $56000.0 in Q1 2026.

• Quarterly Depreciation & Amortization (CF) rose 107.41% year-over-year to $56000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $143000.0 (up 37.5% YoY) and the FY2025 annual result came in at $114000.0, up 8.57% from the prior year.
• Depreciation & Amortization (CF) improved to $56000.0 in Q1 2026, from $34000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $56000.0 in Q1 2026 to a low of $15000.0 in Q4 2022.
• A 5-year average of $26823.5 and a median of $26000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) tumbled 34.78% — and 2026, when it jumped 107.41%.
• Tracing MIST's Depreciation & Amortization (CF) over 5 years: stood at $15000.0 in 2022, then soared by 73.33% to $26000.0 in 2023, then changed by 0.0% to $26000.0 in 2024, then soared by 30.77% to $34000.0 in 2025, then surged by 64.71% to $56000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $56000.0 (Q1 2026), $34000.0 (Q4 2025), and $25000.0 (Q3 2025), per Business Quant data.